Newsletter Signup | Join Community
Initial clinical results for REGN 5458 Bispecific Antibody appear promising for treatment of advanced myeloma.
Management of bone complications, anemia, infections and other complications of Multiple Myeloma
Melflufen demonstrates long term survival benefit in patients with advanced Multiple Myeloma.
January 2020 update on CAR-T therapy in multiple myeloma and other targeted therapies. CAR T looks promising.
CC-932269 is a bispecific antibody being developed for Multiple Myeloma that appears to have anti-myeloma activity.
Darzalex is effective myeloma treatment in several settings - most recently for transplant ineligible patients.
Understand the risks-benefits of Revlimid, Ninlaro & Velcade maintenance therapy for Multiple Myeloma; 2019 ASH update.
Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is…
New Antibody that targets CD74 on myeloma cells gets nod from FDA to proceed. …
UK doctors identify a new target for treating Multiple Myeloma: …